Innovating Works

ImmunAID

Financiado
Immunome project consortium for AutoInflammatory Disorders
Systemic autoinflammatory diseases (SAID) encompass several rare disorders characterised by extensive clinical and biological inflammation. SAID are caused by the dysregulation of the innate immune system. Due to numerous and unsp... Systemic autoinflammatory diseases (SAID) encompass several rare disorders characterised by extensive clinical and biological inflammation. SAID are caused by the dysregulation of the innate immune system. Due to numerous and unspecific symptoms, tentative diagnosis often leads to failure/delay and inadequate treatments. ImmunAID will deliver a method for rapid and accurate diagnosis across all the spectrum of SAID, in order to improve clinical management of SAID patients. Thanks to parallel analyses run on samples from more than 600 patients with monogenic or undiagnosed SAID collected throughout Europe, Immunaid will generate a unique and comprehensive set of data, based on unbiased multiomics approaches (gene, transcript, protein, microbiome), and hypothesis-driven assays exploring inflammasome, inflammation resolution and immune networks. A centralised data management strategy will enable to conduct integrated analyses for diagnostic biomarker identification. In a discovery phase, semi-supervised clustering of omics data will be combined to supervised analysis of pathway-related data to provide robust classification and strong link to clinical features/impact. The related biomarkers will further be validated externally on independent samples and cohorts. Overall, ImmunAID will disentangle the spectrum of SAID, and propose a new omics- and pathogenesis-based SAID classification associated to a clinical decision making algorithm implementable in daily practice. An efficient dissemination plan will target e.g. guideline-forming bodies, the medical community and patients with the help of the ERN RITA and with the objective of turning our results into clinical practice. To further support this, proactive innovation management will be implemented. To reach its ambitious goals, ImmunAID interdisciplinary consortium gathers high-level partners, including the founder of SAID concept, experts in omics science, immunology, bioinformatics, and involves clinicians and patient advocacy groups. ver más
31/10/2024
INSERM
16M€
Duración del proyecto: 78 meses Fecha Inicio: 2018-04-27
Fecha Fin: 2024-10-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2024-10-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
SC1-PM-03-2017: Diagnostic characterisation of rare diseases
Cerrada hace 7 años
Presupuesto El presupuesto total del proyecto asciende a 16M€
Líder del proyecto
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5